CN115667236A - 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用 - Google Patents

1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用 Download PDF

Info

Publication number
CN115667236A
CN115667236A CN202180029971.7A CN202180029971A CN115667236A CN 115667236 A CN115667236 A CN 115667236A CN 202180029971 A CN202180029971 A CN 202180029971A CN 115667236 A CN115667236 A CN 115667236A
Authority
CN
China
Prior art keywords
compound
formula
methyl
hydrogen
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180029971.7A
Other languages
English (en)
Other versions
CN115667236B (zh
Inventor
徐祥清
邱印利
郭强
于民权
赵松
李曲祥
靖鹏
侯媛媛
董莹莹
吴国胜
张双
陆爱军
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nhwa Pharmaceutical Corp
Original Assignee
Nhwa Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nhwa Pharmaceutical Corp filed Critical Nhwa Pharmaceutical Corp
Publication of CN115667236A publication Critical patent/CN115667236A/zh
Application granted granted Critical
Publication of CN115667236B publication Critical patent/CN115667236B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明涉及化学医药领域，尤其涉及1,5‑二氢‑2,4‑苯二氮
Figure DDA0003900896300000012
‑3‑酮衍生物及其应用，本发明提供的1,5‑二氢‑2,4‑苯二氮
Figure DDA0003900896300000013
‑3‑酮衍生物如式I所示化合物，作用于5‑HT2A、5‑HT2C受体，对5‑HT2A的选择性优于或与哌吗色林类似。用于治疗精神分裂症或者帕金森氏病、痴呆症相关的行为紊乱及精神病。本申请化合物抗精神病活性与哌吗色林相当，镇静副作用、运动恶化副作用小于哌吗色林，且心脏毒性小于哌吗色林。

Description

PCT国内申请，说明书已公开。

Claims (14)

  1. PCT国内申请，权利要求书已公开。
CN202180029971.7A 2020-04-26 2021-04-25 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用 Active CN115667236B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010330893 2020-04-26
CN2020103308931 2020-04-26
CN202110288141 2021-03-17
CN2021102881418 2021-03-17
PCT/CN2021/089660 WO2021218863A1 (zh) 2020-04-26 2021-04-25 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用

Publications (2)

Publication Number Publication Date
CN115667236A true CN115667236A (zh) 2023-01-31
CN115667236B CN115667236B (zh) 2024-04-26

Family

ID=78374068

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180029971.7A Active CN115667236B (zh) 2020-04-26 2021-04-25 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用

Country Status (9)

Country Link
US (1) US20230132621A1 (zh)
EP (1) EP4144725A4 (zh)
JP (1) JP2023522078A (zh)
KR (1) KR20230004662A (zh)
CN (1) CN115667236B (zh)
AU (1) AU2021262281A1 (zh)
BR (1) BR112022021228A2 (zh)
CA (1) CA3172692C (zh)
WO (1) WO2021218863A1 (zh)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002843A1 (en) * 1983-12-24 1985-07-04 Nippon Soda Co., Ltd. IMIDAZO AD1.5-a BD PYRIDIN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
WO1997038984A1 (en) * 1996-04-17 1997-10-23 Du Pont Pharmaceuticals Company N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
CN1238689A (zh) * 1996-10-02 1999-12-15 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
WO2001002358A2 (en) * 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated Cyclized amide derivatives for treating or preventing neuronal damage
CN1215054C (zh) * 1997-08-06 2005-08-17 辛根塔参与股份公司 杀微生物的n－磺酰基甘氨酸炔氧基苯乙基酰胺衍生物
WO2008132139A2 (en) * 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
CN101304980A (zh) * 2005-12-24 2008-11-12 贝林格尔·英格海姆国际有限公司 3－(4－哌啶基)－2,3,4,5,－四氢－1,3－苯并二氮杂䓬－2(1h)－酮
CN103702983A (zh) * 2011-05-12 2014-04-02 艾伯维德国有限责任两合公司 苯并氮杂环庚烯衍生物、含有它们的药物组合物及其在治疗中的用途
US20190031605A1 (en) * 2016-01-29 2019-01-31 Ono Pharmaceutical Co., Ltd. Tetrahydronaphthalene derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236882T1 (de) * 1992-12-21 2003-04-15 Smithkline Beecham Corp Bicyklische fibrinogen antagoniste
EP1720836B1 (en) * 2004-02-25 2014-04-16 Eli Lilly And Company 6-substituted 2,3,4,5-tetrahydro-1h-benzo [d]azepines as 5-ht2c receptor agonists
MX2008000717A (es) * 2005-07-15 2008-03-18 Amr Technology Inc Tetrahidrobenzazepinas substituidas con arilo y heteroarilo y uso de las mismas para bloquear la reabsorcion de norepinefrina, dopamina, y serotonina.
CN101778844B (zh) * 2007-07-26 2013-01-02 弗·哈夫曼-拉罗切有限公司 5-ht2a和d3受体的双重调节剂

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985002843A1 (en) * 1983-12-24 1985-07-04 Nippon Soda Co., Ltd. IMIDAZO AD1.5-a BD PYRIDIN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
WO1997038984A1 (en) * 1996-04-17 1997-10-23 Du Pont Pharmaceuticals Company N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
CN1238689A (zh) * 1996-10-02 1999-12-15 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
CN1215054C (zh) * 1997-08-06 2005-08-17 辛根塔参与股份公司 杀微生物的n－磺酰基甘氨酸炔氧基苯乙基酰胺衍生物
WO2001002358A2 (en) * 1999-07-06 2001-01-11 Vertex Pharmaceuticals Incorporated Cyclized amide derivatives for treating or preventing neuronal damage
CN101304980A (zh) * 2005-12-24 2008-11-12 贝林格尔·英格海姆国际有限公司 3－(4－哌啶基)－2,3,4,5,－四氢－1,3－苯并二氮杂䓬－2(1h)－酮
WO2008132139A2 (en) * 2007-04-27 2008-11-06 Ucb Pharma S.A. New heterocyclic derivatives useful for the treatment of cns disorders
CN103702983A (zh) * 2011-05-12 2014-04-02 艾伯维德国有限责任两合公司 苯并氮杂环庚烯衍生物、含有它们的药物组合物及其在治疗中的用途
US20190031605A1 (en) * 2016-01-29 2019-01-31 Ono Pharmaceutical Co., Ltd. Tetrahydronaphthalene derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
田超 等: "选择性5-HT2A 受体反向激动剂哌马色林的药理作用与临床评价", 《临床药物治疗杂志》, pages 15 - 19 *

Also Published As

Publication number Publication date
JP2023522078A (ja) 2023-05-26
CA3172692C (en) 2024-05-14
KR20230004662A (ko) 2023-01-06
CN115667236B (zh) 2024-04-26
EP4144725A4 (en) 2023-10-25
US20230132621A1 (en) 2023-05-04
EP4144725A1 (en) 2023-03-08
CA3172692A1 (en) 2021-11-04
AU2021262281A1 (en) 2022-11-24
BR112022021228A2 (pt) 2022-12-06
WO2021218863A1 (zh) 2021-11-04

Similar Documents

Publication Publication Date Title
RU2470931C2 (ru) Производные оксадиазола и их применение в качестве потенцирующих средств метаботропных глутаматных рецепторов-842
CN107698569B (zh) 作为jak抑制剂的联吡唑衍生物
JP2009503069A (ja) 三環式ベンゾイミダゾール類、および代謝性グルタミン酸塩受容体のモジュレータとしてのそれらの使用
JP2017524005A (ja) オレキシンレセプターモジュレーターとしてのジフルオロピロリジン
JP2010529117A (ja) 代謝型グルタミン酸受容体オキサジアゾールリガンドおよびそれらの増強剤としての使用
JP2020507606A (ja) カルシウムチャネル阻害剤
US20100317674A1 (en) Metabotropic Glutamate-Receptor-Potentiating Isoindolones
JP2019511466A (ja) オレキシン受容体調節因子としてのハロ置換ピペリジン
WO2019062657A1 (zh) 氮杂环类衍生物、其制备方法及其医药用途
CN113549006B (zh) 一种酰胺衍生物及其应用
CN112313220A (zh) Pd-l1拮抗剂化合物
CN115667236B (zh) 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物及其应用
RU2731913C2 (ru) Пиперазиновое производное
JP2024516633A (ja) オレキシン－２受容体アゴニスト活性を有する置換されるアミド大環状化合物
RU2712968C2 (ru) Имидазодиазепиновое соединение
CN116444484A (zh) 1,5-二氢-2,4-苯二氮䓬-3-酮衍生物的盐及应用
CN112513032B (zh) 作为trk受体的调节剂的4-取代的苯基-1,3,5-三嗪衍生物
RU2777915C2 (ru) Имидазодиазепиновое соединение
JPWO2021218863A5 (zh)
CN116354924A (zh) 一种2-咪唑酮衍生物及其应用
JP2024520395A (ja) 置換される縮合二環式大環状化合物および関連のある治療方法
TW201307300A (zh) 趨代謝性麩胺酸受體調節劑

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080583

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 221000 No. 18, Yangshan Road, Xuzhou Economic and Technological Development Zone, Jiangsu Province

Patentee after: NHWA PHARMA. Corp.

Country or region after: China

Address before: 221000 No. 18, Yangshan Road, Xuzhou Economic and Technological Development Zone, Xuzhou, Jiangsu Province

Patentee before: NHWA PHARMA. Corp.

Country or region before: China